HSD17B13 and metabolic dysfunction-associated steatotic liver disease: Thus, our findings suggested that the down-regulation of the high level of HSD17B13 produced a therapeutic effect on NAFLD via improving the abnormal liver lipid metabolism and inflammation; therefore, it might be a good strategy for the treatment of NAFLD, as HSD17B13 expression was normally higher in NAFLD that had been induced by various etiological agents (Figure 1).